1. Home
  2. SKYE vs LSAK Comparison

SKYE vs LSAK Comparison

Compare SKYE & LSAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • LSAK
  • Stock Information
  • Founded
  • SKYE 2012
  • LSAK 1997
  • Country
  • SKYE United States
  • LSAK South Africa
  • Employees
  • SKYE N/A
  • LSAK N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • LSAK Investment Bankers/Brokers/Service
  • Sector
  • SKYE Health Care
  • LSAK Finance
  • Exchange
  • SKYE Nasdaq
  • LSAK Nasdaq
  • Market Cap
  • SKYE 176.8M
  • LSAK N/A
  • IPO Year
  • SKYE N/A
  • LSAK N/A
  • Fundamental
  • Price
  • SKYE $5.89
  • LSAK $4.96
  • Analyst Decision
  • SKYE Strong Buy
  • LSAK
  • Analyst Count
  • SKYE 4
  • LSAK 0
  • Target Price
  • SKYE $19.25
  • LSAK N/A
  • AVG Volume (30 Days)
  • SKYE 386.3K
  • LSAK 44.3K
  • Earning Date
  • SKYE 01-01-0001
  • LSAK 09-10-2024
  • Dividend Yield
  • SKYE N/A
  • LSAK N/A
  • EPS Growth
  • SKYE N/A
  • LSAK N/A
  • EPS
  • SKYE N/A
  • LSAK N/A
  • Revenue
  • SKYE N/A
  • LSAK $551,325,000.00
  • Revenue This Year
  • SKYE N/A
  • LSAK $9.63
  • Revenue Next Year
  • SKYE N/A
  • LSAK $8.35
  • P/E Ratio
  • SKYE N/A
  • LSAK N/A
  • Revenue Growth
  • SKYE N/A
  • LSAK 6.72
  • 52 Week Low
  • SKYE $1.44
  • LSAK $3.00
  • 52 Week High
  • SKYE $19.41
  • LSAK $5.33
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 34.36
  • LSAK 60.42
  • Support Level
  • SKYE $5.95
  • LSAK $4.76
  • Resistance Level
  • SKYE $6.83
  • LSAK $4.84
  • Average True Range (ATR)
  • SKYE 0.82
  • LSAK 0.13
  • MACD
  • SKYE 0.09
  • LSAK 0.02
  • Stochastic Oscillator
  • SKYE 21.26
  • LSAK 89.19

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: